EVO

At a glance

Evotec SE (EVO) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Hamburg, Germany and has 4,461 employees. The company is worth $490.44M. Revenue was €788.37M in fiscal 2025, down 1.1% from the year before. It reported a net loss of €103.52M. The share price is 67.7% below its 52-week high of $4.27. One of the 38 superinvestors we track held it at the end of Q2 2026: Israel Englander (Millennium Management), at $63.93K. No open-market insider trades in it were filed over the last 30 days.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$490.44M

P/E

—

Forward P/E

—

P/B

0.7x

Dividend yield

0.00%

Payout

—

EPS

-$0.64

ROE

-26.07%

Profit margin

-27.47%

Revenue growth

-16.20%

Beta

1.27

52-week high

$4.27

52-week low

$1.33

History

Year by year, from the annual reports; dividends from the payments themselves.

Revenue, debt and profit are in EUR, the currency the company reports in — not converted to dollars. Dividends are in dollars.

Investors holding this

Major managers that reported this stock in their latest 13F.

• IE
  Israel EnglanderHeld

  Millennium Management · Q2 2026
  $63.93K

  22.83K shares · 0.0% of portfolio

Indicators, year by year

The last 4 closed years, each at that year’s closing price and reported numbers.

This company reports in EUR, and the stock trades in dollars. P/E, P/S, P/B and payout would divide dollars by EUR, so they are not shown; EPS is in EUR. Margin, ROE and dividend yield do not depend on the currency.

Median of the years shown; P/E years above 200x are left out.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company